Nordson Corporation (NDSN)

[abrooklyn]

Nordson Corporation Reports First Quarter Fiscal 2023 Results and Updates Annual Guidance

Source: Business Wire
First Quarter:

Sales were $610 million, a 1% organic increase over the prior year
Operating profit was $144 million
Adjusted operating profit was $155 million, 25% of sales
Earnings per share were $1.81
Adjusted earnings per share were $1.95 compared to $2.07 in the prior year
Guidance:

Updating previously issued full-year fiscal 2023 guidance: revenue growth of 0% to 3% over record fiscal 2022 and adjusted earnings per diluted share in the range of $8.75 to $9.50 per share
Nordson Corporation (Nasdaq: NDSN) today reported results for the fiscal first quarter ended January 31, 2023. Sales were $610 million, comparable to the prior year’s first quarter sales of $609 million. The increase in first quarter 2023 sales includes an organic increase of 1% and a favorable acquisition impact of 3%, offset by unfavorable currency translation of 4%. The organic sales increase was driven by strong 9% combined growth in Europe and the Americas, partially offset by weakness in Asia Pacific, predominantly China.

Operating profit in the first quarter was $144 million. Adjusted operating profit, excluding transaction fees, severance and non-cash inventory charges associated with the CyberOptics acquisition, totaled $155 million, or 25% of sales, compared to prior year adjusted operating profit of $157 million. The operating profit, similar to sales, was comparable to the prior year as favorable organic and acquisitive growth was offset by an unfavorable 6% headwind from currency translation. EBITDA for the first quarter of 2023 totaled $181 million, or 30% of sales.

Net income was $104 million, or $1.81 earnings per diluted share. Adjusted net income was $112 million, a $9 million decrease from the prior year earnings of $122 million. The decrease was driven by increased interest expense and foreign currency losses. First quarter 2023 adjusted earnings per diluted share were $1.95, a 6% decrease over the prior year adjusted earnings per diluted share of $2.07.

“First quarter results were in line with our expectations. Our team delivered sales growth comparable to a record fiscal first quarter 2022 despite unfavorable currency headwinds, the timing of the Chinese New Year, and the unexpected negative impact from the spread of COVID-19 in China. Growth was driven by the benefits of our CyberOptics acquisition, as well as solid demand in industrial and medical interventional solutions product lines. The diversity of our geographies and product lines in Europe and Americas, as well as our steadfast dedication to advancing the NBS Next growth framework and responding to the needs of our customers, continues to deliver high quality business performance in dynamic market conditions,” said Sundaram Nagarajan, president and chief executive officer.

First Quarter Segment Results

Industrial Precision Solutions sales of $312 million represents a constant currency growth of 1% over the prior year, offset by unfavorable currency translation impacts. The organic growth of 1% was driven primarily by steady demand across most product lines and regions, offset by softness in the Asia Pacific region due to labor shortages from the spread of COVID-19, as well as the timing of Chinese New Year. Operating profit in the quarter was $102 million, or 33% of sales, comparable to the prior year first quarter.

Medical and Fluid Solutions sales of $154 million decreased 3% compared to the prior year first quarter. Organic sales decreased 1% and currency had an unfavorable impact of 2%. The organic sales decrease was driven by significant softness in the medical fluid components product lines and fluid solutions product lines in China, offset by strong demand for medical interventional solutions product lines. Operating profit totaled $39 million, or 26% of sales, a decrease of 20% compared to the prior year first quarter operating profit. The decreased segment profitability resulted from meaningful sales mix changes within medical product lines and related individual factory inefficiencies due to reduced volumes.

Advanced Technology Solutions sales of $145 million increased 14% compared to the prior year first quarter. Sales benefited from the acquisition impact of 14% and an increase in organic sales of 5%, partially offset by an unfavorable currency impact of 4%. The organic sales increase was driven by test and inspection product lines. Operating profit totaled $17 million. Adjusted operating profit, excluding non-cash inventory and other acquisition-related charges, totaled $27 million, or 19% of sales, which was comparable to the prior year first quarter operating profit. Improvements in profit from the acquisition were offset by unfavorable changes in sales mix and a 5% currency translation headwind.

Outlook

While the backlog remains robust at approximately $1 billion, the backlog is not consistent across the different businesses and is heavily weighted toward systems and medical interventional solutions. Order entry in recent weeks has decreased from the previous run rate and several customers have been pushing delivery dates out into the second half of fiscal 2023. Based on our current visibility, the Company is updating its previously issued full-year revenue growth guidance to 0% to 3% over record fiscal 2022 and narrowing its adjusted earnings guidance to the range of $8.75 to $9.50.

Nordson management will provide additional commentary on these results and outlook during its previously announced webcast on Tuesday, February 21, 2023, at 8:30 a.m. eastern time, which can be accessed at https://investors.nordson.com. For persons unable to listen to the live broadcast, a replay will be available for 14 days after the event. Information about Nordson’s investor relations and shareholder services is available from Lara Mahoney, vice president, investor relations and corporate communications at [phone] or [e-mail].

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by terminology such as “may,” “will,” “should,” “could,” “expects,” “anticipates,” “believes,” “projects,” “forecasts,” “outlook,” “guidance,” “continue,” “target,” or the negative of these terms or comparable terminology. These statements reflect management’s current expectations and involve a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, U.S. and international economic conditions; financial and market conditions; currency exchange rates and devaluations; possible acquisitions, including the Company’s ability to successfully integrate acquisitions; the Company’s ability to successfully divest or dispose of businesses that are deemed not to fit with its strategic plan; the effects of changes in U.S. trade policy and trade agreements; the effects of changes in tax law; and the possible effects of events beyond our control, such as political unrest, including the conflict between Russia and Ukraine, acts of terror, natural disasters and pandemics, including the coronavirus (COVID-19) pandemic and the other factors discussed in Item 1A (Risk Factors) in the Company’s most recently filed Annual Report on Form 10-K and in its Forms 10-Q filed with the Securities and Exchange Commission, which should be reviewed carefully. The Company undertakes no obligation to update or revise any forward-looking statement in this press release.

Nordson Corporation is an innovative precision technology company that leverages a scalable growth framework through an entrepreneurial, division-led organization to deliver top tier growth with leading margins and returns. The Company’s direct sales model and applications expertise serves global customers through a wide variety of critical applications. Its diverse end market exposure includes consumer non-durable, medical, electronics and industrial end markets. Founded in 1954 and headquartered in Westlake, Ohio, the Company has operations and support offices in over 35 countries. Visit Nordson on the web at www.nordson.com, www.twitter.com/Nordson_Corp or www.facebook.com/nordson.

NORDSON CORPORATION

CONSOLIDATED STATEMENTS OF INCOME (Unaudited)

(Dollars in thousands except for per-share amounts)




Three Months Ended



January 31,
2023



January 31,
2022

Sales

$

610,477





$

609,166



Cost of sales



281,610







269,032



Gross profit



328,867







340,134



Gross margin %



53.9

%





55.8

%









Selling & administrative expenses



184,648







184,274



Operating profit



144,219







155,860











Interest expense - net



(9,943

)





(5,185

)

Other income (expense) - net



(3,196

)





1,292



Income before income taxes



131,080







151,967











Income taxes



26,819







31,558











Net income

$

104,261





$

120,409











Weighted-average common shares outstanding:







Basic



57,170







58,152



Diluted



57,762







58,819











Earnings per share:







Basic earnings

$

1.82





$

2.07



Diluted earnings

$

1.81





$

2.05



NORDSON CORPORATION

CONSOLIDATED BALANCE SHEETS (Unaudited)

(Dollars in thousands)




January 31, 2023



October 31, 2022

Cash and cash equivalents

$

121,994



$

163,457

Receivables - net



546,649





537,313

Inventories - net



447,727





383,398

Other current assets



62,046





48,803

Total current assets



1,178,416





1,132,971









Property, plant & equipment - net



361,447





353,442

Goodwill



2,107,113





1,804,693

Other assets



590,447





529,269



$

4,237,423



$

3,820,375









Current maturities of long-term debt and notes payable

$

420,947



$

392,537

Accounts payable and accrued liabilities



404,514





441,666

Total current liabilities



825,461





834,203









Long-term debt



595,166





345,320

Other liabilities



370,111





346,477

Total shareholders' equity



2,446,685





2,294,375



$

4,237,423



$

3,820,375

NORDSON CORPORATION

CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited)

(Dollars in thousands)




Three Months Ended



January 31,
2023



January 31,
2022

Cash flows from operating activities:







Net income

$

104,261





$

120,409



Depreciation and amortization



26,434







25,390



Other non-cash items



6,224







11,023



Changes in working capital



(58,371

)





(29,217

)

Other



44,789







(9,518

)

Net cash provided by operating activities



123,337







118,087











Cash flows from investing activities:







Additions to property, plant and equipment



(9,302

)





(12,491

)

Acquisition of businesses, net of cash acquired



(377,843

)





(171,613

)

Other - net



9







7



Net cash used in investing activities



(387,136

)





(184,097

)









Cash flows from financing activities:







Issuance (repayment) of long-term debt



252,278







(1,257

)

Repayment of finance lease obligations



(1,318

)





(1,640

)

Dividends paid



(37,199

)





(29,724

)

Issuance of common shares



8,807







5,721



Purchase of treasury shares



(6,875

)





(35,002

)

Net cash provided (used) in financing activities



215,693







(61,902

)









Effect of exchange rate change on cash:



6,643







(1,521

)

Net change in cash and cash equivalents



(41,463

)





(129,433

)









Cash and cash equivalents:







Beginning of period



163,457







299,972



End of period

$

121,994





$

170,539



NORDSON CORPORATION

SALES BY GEOGRAPHIC SEGMENT (Unaudited)

(Dollars in thousands)




Three Months Ended



Sales Variance



January 31,
2023



January 31,
2022



Organic



Acquisitions



Currency



Total

SALES BY SEGMENT























Industrial precision solutions

$

311,546



$

323,933



1.2

%



—

%



(5.0

) %



(3.8

) %

Medical and fluid solutions



154,287





158,784



(0.8

) %



—

%



(2.0

) %



(2.8

) %

Advanced technology solutions



144,644





126,449



4.6

%



13.5

%



(3.7

) %



14.4

%

Total sales

$

610,477



$

609,166



1.4

%



2.8

%



(4.0

) %



0.2

%

























SALES BY GEOGRAPHIC REGION























Americas

$

264,878



$

239,901



8.6

%



2.1

%



(0.3

) %



10.4

%

Europe



162,939





155,985



10.7

%



1.3

%



(7.5

) %



4.5

%

Asia Pacific



182,660





213,280



(13.3

) %



4.7

%



(5.8

) %



(14.4

) %

Total sales

$

610,477



$

609,166



1.4

%



2.8

%



(4.0

) %



0.2

%

NORDSON CORPORATION

RECONCILIATION OF NON-GAAP MEASURES - ADJUSTED OPERATING PROFIT AND EBITDA (Unaudited)

(Dollars in thousands)




Three Months Ended



January 31, 2023



January 31, 2022

SALES BY SEGMENT















Industrial precision solutions

$

311,546









$

323,933







Medical and fluid solutions



154,287











158,784







Advanced technology solutions



144,644











126,449







Total sales

$

610,477









$

609,166























OPERATING PROFIT















Industrial precision solutions

$

102,319









$

102,187







Medical and fluid solutions



39,384











49,093







Advanced technology solutions



16,963











27,234







Corporate



(14,447

)









(22,654

)





Total operating profit

$

144,219









$

155,860























OPERATING PROFIT ADJUSTMENTS (1)













Industrial precision solutions

$

—









$

1,563







Advanced technology solutions



10,295











—







Total adjustments

$

10,295









$

1,563























ADJUSTED OPERATING PROFIT (NON-GAAP) (2)





% of Sales







% of Sales

Industrial precision solutions

$

102,319





33

%



$

103,750





32

%

Medical and fluid solutions



39,384





26

%





49,093





31

%

Advanced technology solutions



27,258





19

%





27,234





22

%

Corporate



(14,447

)









(22,654

)





Total operating profit - adjusted

$

154,514





25

%



$

157,423





26

%

















DEPRECIATION & AMORTIZATION













Industrial precision solutions

$

6,845









$

7,442







Medical and fluid solutions



13,625











13,547







Advanced technology solutions



3,812











2,263







Corporate



2,152











2,138







Total depreciation & amortization

$

26,434









$

25,390























EBITDA (NON-GAAP) (2)















Industrial precision solutions

$

109,164





35

%



$

111,192





34

%

Medical and fluid solutions



53,009





34

%





62,640





39

%

Advanced technology solutions



31,070





21

%





29,497





23

%

Corporate



(12,295

)









(20,516

)





Total EBITDA

$

180,948





30

%



$

182,813





30

%

(1)

Represents fees, severance and non-cash inventory charges associated with acquisitions.

(2)

Adjusted operating profit and EBITDA are non-GAAP measures used by management to evaluate the Company's ongoing operations. Adjusted operating profit is defined as operating profit plus certain adjustments, such as fees, severance and non-cash inventory charges associated with acquisitions. EBITDA is defined as adjusted operating profit plus depreciation and amortization.

NORDSON CORPORATION

RECONCILIATION OF NON-GAAP MEASURES - PROFITABILITY (Unaudited)

(Dollars in thousands)




Three Months Ended



January 31, 2023



January 31, 2022

GAAP AS REPORTED







Operating profit

$

144,219





$

155,860



Other / interest expense - net



(13,139

)





(3,893

)

Net income



104,261







120,409



Diluted earnings per share

$

1.81





$

2.05











Shares outstanding - diluted



57,762







58,819











OPERATING PROFIT ADJUSTMENTS







Inventory step-up amortization

$

4,306





$

1,563



Severance and other



5,989







—











Total adjustments

$

10,295





$

1,563











Adjustments net of tax

$

8,189





$

1,238



EPS effect of adjustments and other discrete tax items

$

0.14





$

0.02











NON-GAAP MEASURES-ADJUSTED PROFITABILITY







Operating profit (1)

$

154,514





$

157,423



Operating profit % of sales



25.3

%





25.8

%

Net income (2)

$

112,450





$

121,647



Diluted earnings per share (3)

$

1.95





$

2.07



(1)

Adjusted operating profit is defined as operating profit plus certain adjustments, such as fees, severance, and non-cash inventory charges related to acquisitions. Adjusted operating profit as a percentage of sales is defined as adjusted operating profit divided by sales.

(2)

Adjusted net income is defined as net income plus tax effected adjustments and other discrete tax items.

(3)

Adjusted earnings per share is defined as GAAP EPS adjusted for tax effected adjustments and other discrete tax items.

The Company also uses the non-GAAP financial measure “constant currency” sales or sales “on a constant currency basis” to show changes in our revenue without giving effect to period-to-period currency fluctuations. Constant currency is defined as sales growth excluding the impacts of changes in foreign currencies. We express period over period revenue variances that are calculated in constant currency as a percentage. Because the reconciliation is inherent in the disclosure, we believe that a separate reconciliation would not provide any benefit.

Management uses these non-GAAP measures internally to make strategic decisions, forecast future results, and evaluate the Company's current performance. Given management's use of these non-GAAP measures, the Company believes these measures are important to investors in understanding the Company's current and future operating results as seen through the eyes of management. In addition, management believes these non-GAAP measures are useful to investors in enabling them to better assess changes in the Company's core business across different time periods. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to other companies' non-GAAP financial measures, even if they have similar names. Amounts may not add due to rounding.


View source version on businesswire.com: https://www.businesswire.com/news/home/20230220005225/en/

Lara Mahoney
Vice President, Investor Relations & Corporate Communications
440.204.9985
[e-mail]